Solid Biosciences

This past Sunday, #TeamSolid laced up their shoes and hit the pavement at the Boston Athletic Association 10K, presented by Brigham and Women's Hospital. Our team ranked among the top 10 fundraisers in support of the Arrhythmia Service Fund. Solid remains committed to advancing our pipeline in cardiac diseases and making a tangible impact on cardiac patient care to pave the way for a healthier future. Thank you to everyone who contributed and cheered us on! #BrighamAndWomensHospital #BAA10K #Boston10K #CardiacHealth #PatientCare

The Solid team is headed back to Orlando this week to engage with the Duchenne community at Parent Project Muscular Dystrophy’s 30th Annual Conference, June 27-29. At the conference, our Chief Medical Officer, Gabriel Brooks, M.D., will participate in an industry panel “Research Row: Gene Therapy – Current and Evolving Landscape Session” on Friday, June 28, 1:45 p.m. to share insights about gene therapy and INSPIRE DUCHENNE, Solid’s first-in human clinical study evaluating SGT-003. We look forward to engaging with the Duchenne community in Orlando! For more information, visit: https://lnkd.in/gMhB4CUA  #GeneTherapy #DuchenneMuscularDystrophy #PPMD30

Solid is thrilled to sponsor Parent Project Muscular Dystrophy’s 30th Annual Conference in Orlando, Florida, June 27-29 that aims to empower, educate and unite patients with Duchenne and their families. We are proud to continue our steadfast support of PPMD’s efforts to support the Duchenne community and are grateful for their efforts.   For more information: https://lnkd.in/gMhB4CUA   #GeneTherapy #DuchenneMuscularDystrophy #PPMD30

Aligning with our commitment to ensuring patient perspective is incorporated in our work. We are honored to be a sponsor of an Externally-Led Patient Focused Drug Development Meeting, organized by The SADS Foundation. Scheduled for June 11, this meeting, will collect important information to help ensure scientific and clinical pursuits address unmet needs of patients with rare cardiac conditions, as well as their caregivers and families.   Learn more: https://lnkd.in/gwqUWYQG    #CPVT #PatientFocusedDrugDevelopment

🌟 Learn more about Session Three of Hearts in Rhythm Organization Industry Panel Livestream on Friday, June 7th🌟 🕝 Time: 2:30 p.m. - 3:15 p.m. Eastern 📍 Tune in at: www.sads.ca/hiro2024 or click the link in our bio Session Three: Gene Therapies for Inherited Cardiac Disease Meet the speakers, Dr. Gabriel Brooks (Chief Medical Officer, Solid Biosciences) and Dr. Richie Khanna (Vice President of Nonclinical and Bioanalytical Development, Lexeo Therapeutics), along with moderators Dr. Chris Simpson (Executive Vice President and Chief Medical Executive, Ontario Health), Dr. Shubhayan Sanatani (Pediatric Electrophysiologist, BC Children's Hospital), and Mr. Evan Krueger (Communications Director, Canadian SADS Foundation). Explore the latest approaches for treating catecholaminergic polymorphic ventricular tachycardia (CPVT), focusing on therapies targeting the RYR-2 gene. Additionally, this session will highlight innovative gene therapy efforts aimed at addressing arrhythmogenic cardiomyopathy, specifically targeting the PKP-2 gene. Following the presentations, moderators will engage in a discussion to delve deeper into these groundbreaking therapies. Don't miss this opportunity to learn about the future of gene therapies for inherited cardiac disease! Disclaimer: The Canadian SADS Foundation does not endorse any specific therapeutic or pharmaceutical company. For any specific concerns regarding your health, please consult with your healthcare team.

Our Chief Medical Officer, Gabriel Brooks, M.D., will be participating in the industry panel livestream at the upcoming Hearts in Rhythm Organization Symposium 2024 on June 7, at 2:30 PM ET.    Join to hear Dr. Brooks discuss innovative approaches to combating inherited cardiac diseases through gene therapy.    Learn more at: https://lnkd.in/e7_vxJzN   #HiROSymposium #GeneTherapies #CardiacDisease

Solid is headed to Orlando, Florida this weekend as a proud sponsor of @CureDuchenne’s FUTURES 2024 National Conference. Our Senior Director, Clinical Sciences, Patrick Gonzalez, Ph.D., will be participating in the Scientific session “Gene Therapy Approaches to Treatment” on Friday, May 24, 10 a.m., to share insights about gene therapy and INSPIRE DUCHENNE, Solid’s first-in human clinical study evaluating SGT-003. For more information on the conference, visit: https://lnkd.in/gn5vHUnn #LetsCureDuchenne #CureDuchenne #2024FUTURES #WeWILLCureDuchenne

We are looking forward to engaging with the Duchenne community at the annual CureDuchenne FUTURES National Conference, which brings education, connection, and hope to patients with Duchenne and their families. As a proud sponsor, we are thrilled to support the important efforts of CureDuchenne and help support those impacted by Duchenne. For more information on the conference, visit: https://lnkd.in/gn5vHUnn #LetsCureDuchenne #CureDuchenne #2024FUTURES #WeWILLCureDuchenne

Solid Biosciences today reported Q1 2024 financial results and provided a business update. Read the full release: https://lnkd.in/ebaYjftG

Are you attending #ASGCT2024? Don’t miss our Senior Principal Scientist, E Xiaofei present “Novel Mechanism to Increase AAV Yield through Blocking AAV Transduction of Manufacturing HEK293 Cells During AAV Production” during session “AAV Manufacturing I.” Join us for the oral presentation at 2:15-2:30 PM ET, Ballroom 3. Learn more: https://lnkd.in/gSjPsVn  American Society of Gene & Cell Therapy #CellTherapy #GeneTherapy #ASGCT